Empagliflozin for non-diabetic metabolic dysfunction-associated steatotic liver disease: a promising therapeutic agent in transition.
作者信息
El-Kassas Mohamed, Liu Hongqun, Lee Samuel S
机构信息
Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA), Cairo, Egypt.
出版信息
Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):651-654. doi: 10.21037/hbsn-2025-250. Epub 2025 Jul 25.
Abstract
摘要
Zotero 插件